Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | NMT1 | P30419 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 10/20 | 0.37 |
| ▸ | GUSB | P08236 | 4/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566922 | 1.00 | EGFR (0.38) | EGFRNMT1HTR6GUSBHTR1A | |
| SCHEMBL24310372 | 0.93 | HTR6 (0.37) | EGFRHTR6GUSBLCK | |
| SCHEMBL29567188 | 0.93 | HTR6 (0.37) | EGFRHTR6GUSBLCK | |
| SCHEMBL24310583 | 0.88 | RIPK2 (0.38) | HTR6GUSBLCK | |
| SCHEMBL26858387 | 0.88 | GUSB (0.42) | HTR6GUSB | |
| SCHEMBL29566942 | 0.86 | BRD4 (0.40) | EGFRHTR6HTR1AHTR2CHTR7 | |
| SCHEMBL26809802 | 0.86 | BRD4 (0.40) | EGFRHTR6HTR1AHTR2CHTR7 | |
| SCHEMBL29567043 | 0.85 | HTR6 (0.37) | NMT1HTR6GUSBHTR1AHTR2C | |
| SCHEMBL26837336 | 0.85 | HTR6 (0.37) | NMT1HTR6GUSBHTR1AHTR2C | |
| SCHEMBL26809994 | 0.85 | GUSB (0.36) | HTR6GUSBLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | EGFR 818/4885NMT1 266/4885HTR6 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.